PURPOSE: The principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: In this multicenter, two-stage, phase II study, abiraterone acetate 1,000 mg was administered once daily continuously. The primary end point was achievement of a prostate-specific antigen (PSA) decline of >; or = 50% in at least seven of 35 patients. Per an attained phase II design, more than 35 patients could be enrolled if the primary end point was met. Secondary objectives included: PSA declines of > or = 30% and > or = 90%; rate of RECIST (Response Evaluation Criteria in Solid Tumors) responses and duration on study; time to PSA progression; safety and tolerability; and circulating tumor cell (CTC) enumeration. RESULTS:Docetaxel-treated patients with CRPC (N = 47) were enrolled. PSA declines of > or = 30%, > or = 50% and > or = 90% were seen in 68% (32 of 47), 51% (24 of 47), and 15% (seven of 47) of patients, respectively. Partial responses (by RECIST) were reported in eight (27%) of 30 patients with measurable disease. Median time to PSA progression was 169 days (95% CI, 113 to 281 days). The median number of weeks on study was 24, and 12 (25.5%) of 47 patients remained on study > or = 48 weeks. CTCs were enumerated in 34 patients; 27 (79%) of 34 patients had at least five CTCs at baseline. Eleven (41%) of 27 patients had a decline from at least five to less than 5 CTCs, and 18 (67%) of 27 had a > or = 30% decline in CTCs after starting treatment with abiraterone acetate. Abiraterone acetate was well tolerated. CONCLUSION:Abiraterone acetate has significant antitumor activity in post-docetaxel patients with CRPC. Randomized, phase III trials of abiraterone acetate are underway to define the future role of this agent.
RCT Entities:
PURPOSE: The principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: In this multicenter, two-stage, phase II study, abiraterone acetate 1,000 mg was administered once daily continuously. The primary end point was achievement of a prostate-specific antigen (PSA) decline of > or = 50% in at least seven of 35 patients. Per an attained phase II design, more than 35 patients could be enrolled if the primary end point was met. Secondary objectives included: PSA declines of > or = 30% and > or = 90%; rate of RECIST (Response Evaluation Criteria in Solid Tumors) responses and duration on study; time to PSA progression; safety and tolerability; and circulating tumor cell (CTC) enumeration. RESULTS:Docetaxel-treated patients with CRPC (N = 47) were enrolled. PSA declines of > or = 30%, > or = 50% and > or = 90% were seen in 68% (32 of 47), 51% (24 of 47), and 15% (seven of 47) of patients, respectively. Partial responses (by RECIST) were reported in eight (27%) of 30 patients with measurable disease. Median time to PSA progression was 169 days (95% CI, 113 to 281 days). The median number of weeks on study was 24, and 12 (25.5%) of 47 patients remained on study > or = 48 weeks. CTCs were enumerated in 34 patients; 27 (79%) of 34 patients had at least five CTCs at baseline. Eleven (41%) of 27 patients had a decline from at least five to less than 5 CTCs, and 18 (67%) of 27 had a > or = 30% decline in CTCs after starting treatment with abiraterone acetate. Abiraterone acetate was well tolerated. CONCLUSION:Abiraterone acetate has significant antitumor activity in post-docetaxelpatients with CRPC. Randomized, phase III trials of abiraterone acetate are underway to define the future role of this agent.
Authors: Joost F Swennenhuis; Arjan G J Tibbe; Rianne Levink; Ronald C J Sipkema; Leon W M M Terstappen Journal: Cytometry A Date: 2009-06 Impact factor: 4.355
Authors: Howard I Scher; Xiaoyu Jia; Johann S de Bono; Martin Fleisher; Kenneth J Pienta; Derek Raghavan; Glenn Heller Journal: Lancet Oncol Date: 2009-02-11 Impact factor: 41.316
Authors: D Olmos; H-T Arkenau; J E Ang; I Ledaki; G Attard; C P Carden; A H M Reid; R A'Hern; P C Fong; N B Oomen; R Molife; D Dearnaley; C Parker; L W M M Terstappen; J S de Bono Journal: Ann Oncol Date: 2008-08-11 Impact factor: 32.976
Authors: R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701
Authors: Gerhardt Attard; Alison H M Reid; Timothy A Yap; Florence Raynaud; Mitch Dowsett; Sarah Settatree; Mary Barrett; Christopher Parker; Vanessa Martins; Elizabeth Folkerd; Jeremy Clark; Colin S Cooper; Stan B Kaye; David Dearnaley; Gloria Lee; Johann S de Bono Journal: J Clin Oncol Date: 2008-07-21 Impact factor: 44.544
Authors: Gerhardt Attard; Joost F Swennenhuis; David Olmos; Alison H M Reid; Elaine Vickers; Roger A'Hern; Rianne Levink; Frank Coumans; Joana Moreira; Ruth Riisnaes; Nikhil Babu Oommen; George Hawche; Charles Jameson; Emilda Thompson; Ronald Sipkema; Craig P Carden; Christopher Parker; David Dearnaley; Stan B Kaye; Colin S Cooper; Arturo Molina; Michael E Cox; Leon W M M Terstappen; Johann S de Bono Journal: Cancer Res Date: 2009-04-01 Impact factor: 12.701
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Sunita R Setlur; Kirsten D Mertz; Yujin Hoshida; Francesca Demichelis; Mathieu Lupien; Sven Perner; Andrea Sboner; Yudi Pawitan; Ove Andrén; Laura A Johnson; Jeff Tang; Hans-Olov Adami; Stefano Calza; Arul M Chinnaiyan; Daniel Rhodes; Scott Tomlins; Katja Fall; Lorelei A Mucci; Philip W Kantoff; Meir J Stampfer; Swen-Olof Andersson; Eberhard Varenhorst; Jan-Erik Johansson; Myles Brown; Todd R Golub; Mark A Rubin Journal: J Natl Cancer Inst Date: 2008-05-27 Impact factor: 13.506
Authors: Charles J Ryan; Shreya Shah; Eleni Efstathiou; Matthew R Smith; Mary-Ellen Taplin; Glenn J Bubley; Christopher J Logothetis; Thian Kheoh; Christine Kilian; Christopher M Haqq; Arturo Molina; Eric J Small Journal: Clin Cancer Res Date: 2011-06-01 Impact factor: 12.531
Authors: Adegoke O Adeniji; Barry M Twenter; Michael C Byrns; Yi Jin; Jeffrey D Winkler; Trevor M Penning Journal: Bioorg Med Chem Lett Date: 2011-01-07 Impact factor: 2.823
Authors: Carsten-H Ohlmann; Axel S Merseburger; Henrik Suttmann; David Schilling; Lutz Trojan; Carsten Kempkensteffen; Stefan Corvin; Michael J Mathers; Patrick J Bastian Journal: World J Urol Date: 2011-11-20 Impact factor: 4.226
Authors: Adegoke O Adeniji; Barry M Twenter; Michael C Byrns; Yi Jin; Mo Chen; Jeffrey D Winkler; Trevor M Penning Journal: J Med Chem Date: 2012-02-15 Impact factor: 7.446
Authors: Mo Chen; Adegoke O Adeniji; Barry M Twenter; Jeffrey D Winkler; David W Christianson; Trevor M Penning Journal: Bioorg Med Chem Lett Date: 2012-03-29 Impact factor: 2.823